By Billy Candra 
This groundbreaking innovation, detailed in a new study published today in the prestigious journal Neuro-Oncology, represents a significant leap forward in neurological diagnostics. The method, a collaborative effort between scientists at the University of Nottingham and clinicians at Nottingham University Hospitals NHS Trust (NUH), promises to revolutionise the diagnostic pathway for one of the most aggressive and challenging forms of cancer.
The Urgent Need for Speed: Addressing a Critical Diagnostic Gap
Brain tumours pose a formidable challenge to modern medicine, both in their diagnosis and treatment. Affecting over 12,000 people annually in the UK, with 34 new diagnoses every day, these tumours often carry a grim prognosis, particularly for the most aggressive types where average survival can be less than a year. The complexity of brain tumours necessitates intricate genetic testing to accurately classify them, a process that has historically been plagued by significant delays.
Traditionally, once a brain tumour is suspected following an MRI scan, patients undergo surgery to obtain a tissue sample. This sample is then sent to centralised analysis facilities for extensive genetic profiling to identify specific DNA abnormalities that determine the tumour type and guide treatment strategies. This multi-week waiting period – often extending to 6-8 weeks or even longer – is not only an incredibly traumatic experience for patients and their families, leaving them in a state of agonizing uncertainty, but also critically delays the commencement of vital treatments such as radiotherapy and chemotherapy. Such delays can profoundly impact the efficacy of these interventions, potentially reducing a patient’s chances of survival and quality of life. The emotional toll of this prolonged waiting period, as many patient advocacy groups highlight, is immense, adding to the already overwhelming stress of a cancer diagnosis.
A New Era of Diagnosis: Two-Hour Turnaround
The team of experts in Nottingham has now developed an ultra-rapid method of genetic diagnosis that promises to eliminate this critical delay. This novel approach compresses a process that once took months into a matter of hours, with diagnostic results potentially available to the surgeon during the operation itself. This real-time information could fundamentally transform surgical decision-making, allowing for more precise and effective interventions tailored to the tumour’s exact genetic profile.
Dr. Stuart Smith, a distinguished Neurosurgeon from the School of Medicine at the University and within NUH, underscored the transformative potential of this development. "Traditionally, the process of diagnosing brain tumours has been slow and expensive," he stated. "Now, with this new technology, we can do more for patients because we can get answers so much more quickly, which will have a much bigger influence on clinical decision making, in as little as two hours. Patients find waiting many weeks for results extremely difficult, and this adds to the anxiety and worry at what is already a very difficult time." Dr. Smith further elaborated on the intraoperative implications: "This type of operation can be quite long, so potentially, a surgeon could be informed during surgery of the accurate diagnosis, which would then impact on the surgical strategy." This ability to adapt surgical plans based on immediate, precise genetic data represents a paradigm shift in neuro-oncological surgery.
The Scientific Backbone: Nanopore Sequencing and ROBIN Software
The core of this revolutionary diagnostic method lies in advanced sequencing technology and innovative software. Professor Matt Loose, a biologist from the School of Life Sciences at the University of Nottingham, spearheaded the development of a method to sequence specific parts of human DNA at higher depth using portable sequencing devices from Oxford Nanopore Technologies. These devices are renowned for their ability to deliver real-time, long-read sequencing data, a distinct advantage over traditional sequencing platforms.
The method developed by Professor Loose allows relevant parts of the human genome to be examined much more quickly, simultaneously sequencing multiple regions of DNA. This significantly speeds up the entire diagnostic process. The team has successfully applied this method to genetically test brain tumour samples, yielding highly accurate results.
At the heart of the analytical process is ROBIN, a sophisticated software tool designed to work with P2 PromethION nanopore sequencers. ROBIN sequences DNA by detecting changes in electrical current as single molecules of DNA pass through a nanopore – an incredibly tiny hole – in a membrane. This direct detection mechanism bypasses the need for several preparatory steps required by other sequencing methods, contributing to its unparalleled speed.
Professor Loose reflected on the journey: "When we first were able to sequence an entire human genome in 2018, it took around five labs and six months to do, which obviously isn’t ideal when time is of the essence for a patient. This new method now allows us to choose the bits of DNA that we need to look at in order to answer specific questions, such as what type of tumour and how can it be treated. Combined with our later research where we were able to look at relevant parts of the human genome more quickly – then we now have a process where we can use ROBIN to create comprehensive classifications of tumours more quickly."
A crucial aspect of this rapid classification involves methylation profiling. "Once we have a sample from a patient, we can now quickly extract the DNA and look at the different properties to give us the information we need. Methylation is the one we are most interested in early on in this instance because that defines the tumour type," Professor Loose explained. DNA methylation patterns are epigenetic modifications that play a critical role in gene regulation and have emerged as highly reliable biomarkers for classifying brain tumours, particularly in line with the latest World Health Organization (WHO) classification updates that emphasize molecular characteristics over purely histological ones.
Clinical Validation and Proven Efficacy
The efficacy and reliability of this novel approach have been rigorously tested. In the published work, the clinical team at NUH successfully utilised the new method during 50 brain tumour surgeries. This involved delivering rapid, intraoperative diagnoses, achieving a remarkable 100% success rate. Diagnostic results were consistently provided in under two hours from surgery, with detailed tumour classifications available within minutes of sequencing initiation. Furthermore, the platform’s capacity for continuous sequencing allows for a fully integrated, comprehensive diagnosis within 24 hours, ensuring that even the most complex molecular details are captured without significant delay.
Dr. Simon Paine, a Consultant Neuropathologist at NUH, lauded the breakthrough, stating, "This new method of diagnosing brain tumours is going to be a game changer; it really is revolutionary. It not only increases the speed at which the results will be available, but the degree of accuracy of the diagnosis as well is incredible." The combination of speed and enhanced accuracy offers unprecedented advantages, ensuring that patients receive the most precise diagnosis possible, which is paramount for guiding effective treatment strategies.
Broader Implications: Transforming Patient Pathways and Healthcare Economics
The implications of this rapid diagnostic method extend far beyond the operating theatre. For patients, the most immediate and profound impact will be the drastic reduction in anxiety and uncertainty. Instead of enduring weeks of agonizing wait, they will receive a definitive diagnosis within hours, allowing for quicker emotional processing and, crucially, the prompt initiation of tailored treatment plans. This accelerated pathway to treatment is expected to significantly improve patient outcomes, particularly for aggressive tumour types where every day counts. Early and precise molecular diagnosis enables clinicians to match patients to the most effective therapies, including targeted drugs and participation in personalized clinical trials.
The economic benefits of this innovation are also substantial. Professor Loose highlighted that "Not only is the test more accurate and quicker, but it is also cheaper than current methods." He estimates the cost to be around £450 per person, with potential for further reduction when scaled up. This cost-effectiveness stems from the method’s ability to consolidate several separate tests into one comprehensive analysis, thereby reducing overall resource consumption and eliminating the need for multiple, expensive individual assays. The current diagnostic landscape often involves a battery of tests, including various immunohistochemical stains, FISH (Fluorescence In Situ Hybridization) for specific genetic alterations, and array-based methods for methylation profiling, each incurring separate costs and turnaround times. By integrating this information into a single, rapid test, the Nottingham method offers a more streamlined and economically viable solution.
Dr. Simon Newman, Chief Scientific Officer at The Brain Tumour Charity, echoed these sentiments, emphasizing the patient-centric advantages: "The delivery of an accurate diagnosis within hours of surgery will be transformative for all patients, ensuring rapid access to the optimal standard of care and – crucially – removing the uncertainty patients face when having to wait weeks for their diagnosis and prognosis." He further noted the systemic benefits: "The potential to combine so many separate tests into one and deliver at a localised level is a game changer for driving equity of access to rapid and accurate molecular diagnosis." This decentralised capability, leveraging portable nanopore technology, means that advanced genetic testing could become accessible to a wider range of hospitals, reducing reliance on distant, centralized laboratories and potentially overcoming geographical disparities in healthcare access.
The Road Ahead: National Rollout and Future Horizons
The team is now actively pursuing the rollout of this new testing method across NHS Trusts throughout the UK. This national implementation will be critical to ensuring that all eligible brain tumour patients can benefit from this accelerated diagnostic pathway. The BRAIN MATRIX Trial, funded by The Brain Tumour Charity, is already exploring how this technology can effectively match patients to personalized clinical trials across the UK, further cementing its role in advancing precision oncology.
Looking further ahead, the implications of this technology extend beyond brain tumours. The principles of rapid, targeted genetic sequencing using portable devices could be applied to diagnose other cancers and diseases where timely molecular information is critical. The ability to perform complex genetic analyses at the point of care, rather than relying on large, specialized laboratories, opens doors for more agile and responsive healthcare systems globally. This move towards decentralized, rapid molecular diagnostics represents a significant step in the broader shift towards personalized medicine, where treatment decisions are increasingly guided by an individual’s unique genetic makeup.
The Nottingham breakthrough is more than just a scientific achievement; it is a beacon of hope for thousands of patients facing a daunting diagnosis. By dramatically cutting diagnostic waiting times and offering unparalleled accuracy and cost-effectiveness, this ultra-rapid method of genetically classifying brain tumours stands poised to redefine patient care, improve outcomes, and alleviate immense suffering across the UK and potentially worldwide.
